Contribution of Rho kinase to blood pressure elevation and vasoconstrictor responsiveness in type 2 diabetic Goto-Kakizaki rats

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1160-1169

  Rao, Milly Y ^a   Soliman, Hesham ^a   Bankar, Girish ^a   Lin, Guorong ^a   MacLeod, Kathleen M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

blood pressure; fasudil; mesenteric resistance arteries; phenylephrine; Rho kinase activity; U 46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; H 1152; PHENYLEPHRINE; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; MALE; MESENTERIC ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 84877582613     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328360383a     Document Type: Article

References (38)

1. Dai S, Robitaille C, Bancej C, Loukine L, Waters C, Baclic O. Executive summary: report from the Canadian Chronic Disease Surveillance System-hypertension in Canada, 2010. Chronic Dis Can 2010; 31:46-47.
2. Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep 2012; 14:89-96.
3. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11:319-325.
4. Komers R. Rho kinase inhibition in diabetic nephropathy. Curr Opin Nephrol Hypertens 2011; 20:77-83.
5. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009; 58:215-226.
6. Lin G, Craig GP, Zhang L, Yuen VG, Allard M, McNeill JH, et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res 2007; 75:51-58.
7. Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, et al. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin 2011; 32:999-1008.
8. Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 2004; 44:796-799.
9. Jin L, Ying Z, Hilgers RH, Yin J, Zhao X, Imig JD, et al. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther 2006; 318:288-295.
10. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001; 15:1062-1064.
11. Asano M, Nomura Y. Comparison of inhibitory effects of Y-27632, a Rho kinase inhibitor, in strips of small and large mesenteric arteries from spontaneously hypertensive and normotensive Wistar-Kyoto rats. Hypertens Res 2003; 26:97-106.
12. Weber DS, Webb RC. Enhanced relaxation to the rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology 2001; 63:129-133.
13. Didion SP, Lynch CM, Faraci FM. Cerebral vascular dysfunction in TallyHo mice: a new model of type II diabetes. Am J Physiol Heart Circ Physiol 2007; 292:H1579-H1583.
14. Nuno DW, Harrod JS, Lamping KG. Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2009; 297:H1469-H1477.
15. Matsumoto T, Kakami M, Kobayashi T, Kamata K. Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 2008; 29:1338-1346.
16. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 1976; 119:85-90.
17. Portha B, Serradas P, Bailbe D, Suzuki K, Goto Y, Giroix MH. Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 1991; 40:486-491.
18. Witte K, Jacke K, Stahrenberg R, Arlt G, Reitenbach I, Schilling L, et al. Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state. Nitric Oxide 2002; 6:85-95.
19. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001; 37:433-439.
20. Gronholm T, Cheng ZJ, Palojoki E, Eriksson A, Backlund T, Vuolteenaho O, et al. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. Eur J Pharmacol 2005; 519:267-276.
21. Mueed I, Zhang L, MacLeod KM. Role of the PKC/CPI-17 pathway in enhanced contractile responses of mesenteric arteries from diabetic rats to alpha-adrenoceptor stimulation. Br J Pharmacol 2005; 146:972-982.
22. Tamura M, Nakao H, Yoshizaki H, Shiratsuchi M, Shigyo H, Yamada H, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005; 1754:245-252.
23. Rattan S, Patel CA. Selectivity of ROCK inhibitors in the spontaneously tonic smooth muscle. Am J Physiol Gastrointest Liver Physiol 2008; 294:G687-G693.
24. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling aftermyocardial infarction inmice. Circulation2004; 109:2234-2239.
25. Sandu OA, Ragolia L, Begum N. Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 2000; 49:2178-2189.
26. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 2003; 92:1337-1343.
27. Sachidanandam K, Harris A, Hutchinson J, Ergul A. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp Biol Med (Maywood) 2006; 231:1016-1021.
28. Brondum E, Kold-Petersen H, Nilsson H, Flyvbjerg A, Aalkjaer C. Increased contractility to noradrenaline and normal endothelial function in mesenteric small arteries from the Goto-Kakizaki rat model of type 2 diabetes. J Physiol Sci 2008; 58:333-339.
29. Kold-Petersen H, Brondum E, Nilsson H, Flyvbjerg A, Aalkjaer C. Impaired myogenic tone in isolated cerebral and coronary resistance arteries from the Goto-Kakizaki rat model of type 2 diabetes. J Vasc Res 2012; 49:267-278.
30. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001; 37 (2 Part 2):414-418.
31. Witte K, Reitenbach I, Stolpe K, Schilling L, Kirchengast M, Lemmer B. Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats. J Cardiovasc Pharmacol 2003; 41:890-896.
32. Lee JH, Xia S, Ragolia L. Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. Am J Physiol Regul Integr Comp Physiol 2008; 295:R144-R154.
33. Budzyn K, Paull M, Marley PD, Sobey CG. Segmental differences in the roles of rho-kinase and protein kinase C in mediating vasoconstriction. J Pharmacol Exp Ther 2006; 317:791-796.
34. Martinsen A, Yerna X, Rath G, Gomez EL, Dessy C, Morel N. Different effect of Rho kinase inhibition on calcium signaling in rat isolated large and small arteries. J Vasc Res 2012; 49:522-533.
35. Grisk O, Schluter T, Reimer N, Zimmermann U, Katsari E, Plettenburg O, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens 2012; 30:980-989.
36. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008; 21:1288-1291.
37. Lu X, Kassab GS. Assessment of endothelial function of large, medium, and small vessels: a unified myograph. Am J Physiol Heart Circ Physiol 2011; 300:H94-H100.
38. Zhang RZ, Gashev AA, Zawieja DC, Davis MJ. Length-tension relationships of small arteries, veins, and lymphatics from the rat mesenteric microcirculation. Am J Physiol Heart Circ Physiol 2007; 292:H1943-H1952.